

Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia

Guideline Number: MMG187.D

Effective Date: October 1, 2023

[➔ Instructions for Use](#)

Table of Contents	Page
Coverage Rationale	1
Documentation Requirements	1
Definitions	1
Applicable Codes	2
References	2
Guideline History/Revision Information	2
Instructions for Use	2

Related Policies
None

Coverage Rationale

Percutaneous Neuroablation is proven and medically necessary for the treatment of pancreatic cancer pain, severe cancer pain and Trigeminal Neuralgia.

For medical necessity clinical coverage criteria, refer to the InterQual® CP: Procedures, Neuroablation, Percutaneous.

Click [here](#) to view the InterQual® criteria.

Documentation Requirements

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The documentation requirements outlined below are used to assess whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

Required Clinical Information
<p>Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain and Trigeminal Neuralgia</p> <p>Medical notes documenting the following, when applicable:</p> <ul style="list-style-type: none"> • Diagnosis • History of the medical condition(s) requiring treatment or surgical intervention • Documentation of signs and symptoms; including onset, duration, and frequency • Physical exam • Relevant medical history • Treatments tried, failed, or contraindicated; include the dates and reason for discontinuation

Definitions

Percutaneous Neuroablation: Percutaneous Neuroablation is a procedure utilized to destroy neural tissue to relieve pain. These procedures may be performed using one of several mechanisms. Chemical neuroablation involves the percutaneous

administration of phenol or alcohol around a nerve to denervate it. Percutaneous application of heat (radiofrequency neuroablation) or cold (cryoneurolysis) to the nerve is called thermal Neuroablation. (InterQual, 2023)

Trigeminal Neuralgia: Trigeminal Neuralgia (TN) is a neuropathic pain syndrome which affects the trigeminal nerve. It is characterized by severe electric shock-like painful episodes in one or more divisions of the trigeminal nerve. The first-line treatment of TN commonly involves medical management with use of analgesic and/or antiepileptic drugs. However, TN can be refractory to pharmacotherapy which necessitates the utilization of various invasive or minimally invasive procedures. (Texakalidis et al., 2019)

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
64600	Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch
64605	Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale
64610	Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring
64620	Destruction by neurolytic agent, intercostal nerve
64640	Destruction by neurolytic agent; other peripheral nerve or branch

CPT® is a registered trademark of the American Medical Association

References

InterQual Neuroablation, Percutaneous Procedures, March Version, © 2023 Change Healthcare LLC. All Rights Reserved.

Texakalidis P, Xenos D, Tora MS, et al. Comparative safety and efficacy of percutaneous approaches for the treatment of trigeminal neuralgia: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2019 Jul;182:112-122.

Guideline History/Revision Information

Date	Summary of Changes
10/01/2023	Supporting Information <ul style="list-style-type: none">Updated <i>References</i> section to reflect the most current informationArchived previous policy version MMG187.C

Instructions for Use

This Medical Management Guideline provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this guideline, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Management Guideline is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare West Medical Management Guidelines are intended to be used in connection with the

independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Member benefit coverage and limitations may vary based on the member's benefit plan Health Plan coverage provided by or through UnitedHealthcare of California, UnitedHealthcare Benefits Plan of California, UnitedHealthcare of Oklahoma, Inc., UnitedHealthcare of Oregon, Inc., UnitedHealthcare Benefits of Texas, Inc., or UnitedHealthcare of Washington, Inc.